Primarily involved in the production, packaging and storage of patient kits for clinical trials, Catalent currently employs over 200 people at its Westhoughton site – and another 50 jobs are to be created.
The new jobs are to meet growing demand in clinical trials from both UK and global customers, and will be in a variety of roles across all departments including operations, engineering, project management and quality.
“The facility at Westhoughton plays a pivotal role in Catalent’s global network, and we are proud of the work we undertake to improve medicines, and the health of patients,” commented Alan Robinson, General Manager. He added: “Over the last twenty years, this site has seen significant growth and investment, and this major recruitment drive reinforces Catalent’s commitment not only to the industry, but the community in and around Westhoughton.”
The Westhoughton site was completed in the summer of 1996 and the company, then known as Unipack and Unival, relocated its 70 staff from premises in nearby Walkden. In February the following year, the facility was officially opened by Her Royal Highness Princess Anne, the Princess Royal. Previously owned by Cardinal Health, the company was purchased by Blackstone in 2007 and became Catalent.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue.